- Study Director: Bruce Miller, MD
- Official Study Title: Establishment of Frontotemporal Dementia Patient Induced Pluripotent Stem (iPS) Cell Lines
- Conditions Studied: Frontotemporal dementia (FTD), Alzheimer’s disease (AD) and other closely related neurological disorders including corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and amyotrophic lateral sclerosis (ALS) with dementia
Purpose of the Study
The purpose of this study is to study the disease-causing mechanisms of frontotemporal dementia (FTD) and create models to study neurological diseases for which there are not adequate human or animal models.
Eligibility
Inclusion Criteria: Participants must have a diagnosis of frontotemporal dementia (FTD) and a known or potential genetic alteration causing the disease. Patients with other closely related neurological disorders, healthy unaffected relatives and other healthy controls may also be included.
Exclusion Criteria: Subjects carrying infectious diseases (e.g., HIV, HCV, HBV, syphilis) will be excluded for laboratory safety reasons. Subjects with known wound-healing problems will be excluded.
What to Expect
Testing: A skin biopsy and virus testing for HIV, hepatitis B and C, and syphilis
The Frequency of Visits: One visit
Materials Needed Before Evaluation: None
Costs: No costs will be charged for any of the study procedures. Participants are responsible for their travel and hotel, should they choose to stay in one.
Contact information
If you are interested in participating in this study or have any questions, please contact the study coordinator, Anna Karydas, at [email protected] or 415.476.3377.